1. Anti-infection
  2. HBV
    HCV
  3. Merimepodib

Merimepodib (Synonyms: VX-497; MMPD)

Cat. No.: HY-13986 Purity: 98.91%
Handling Instructions

Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

For research use only. We do not sell to patients.

Merimepodib Chemical Structure

Merimepodib Chemical Structure

CAS No. : 198821-22-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 112 In-stock
Estimated Time of Arrival: December 31
5 mg USD 113 In-stock
Estimated Time of Arrival: December 31
10 mg USD 200 In-stock
Estimated Time of Arrival: December 31
50 mg USD 650 In-stock
Estimated Time of Arrival: December 31
100 mg USD 950 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 5 publication(s) in Google Scholar

Top Publications Citing Use of Products

    Merimepodib purchased from MCE. Usage Cited in: Antiviral Res. 2018 Jan;149:34-40.

    Reduction in virus production is significantly enhanced in combinations of MMPD and RBV compared with either agent alone, with up to 3 log reduction in virus titer relative to untreated control.

    Merimepodib purchased from MCE. Usage Cited in: Mol Immunol. 2019 Oct;114:226-232.

    IBRS-2 cells in 12-well plates are infected with 100 TCID50 FMDV O/MY98/BY/2010. The cells were treated with or without Merimepodib at indicated concentration for 12 h. The FMDV antigens were determined by IFA, the green fluorescence represents the intracelluar distribution of FMDV.

    Merimepodib purchased from MCE. Usage Cited in: Mol Immunol. 2019 Oct;114:226-232.

    The viral VP1 protein and β-actin are detected by western blot. β-actin was used as an internal control. A serial dilution of guanosine (from 100 μM to 25μM) are added to FMDV infected IBRS-2 cells, when treated with 25 μM merimepodib for 48 h. Cell viability and VP1 protein is analysed as described above.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

    In Vitro

    VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal[1]. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine[2].

    In Vivo

    Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation[1]. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals[3].

    Clinical Trial
    Molecular Weight

    452.46

    Formula

    C₂₃H₂₄N₄O₆

    CAS No.

    198821-22-6

    SMILES

    O=C(O[[email protected]@H]1COCC1)NCC2=CC=CC(NC(NC3=CC=C(C4=CN=CO4)C(OC)=C3)=O)=C2

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 31 mg/mL (68.51 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.2101 mL 11.0507 mL 22.1014 mL
    5 mM 0.4420 mL 2.2101 mL 4.4203 mL
    10 mM 0.2210 mL 1.1051 mL 2.2101 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References
    Cell Assay
    [2]

    The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM l-glutamine. EMCV is infected at 500 PFU/107 L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Purity: 98.91%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    MerimepodibVX-497MMPDVX497VX 497HBVHCVHepatitis B virusHepatitis C virusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product name:
    Merimepodib
    Cat. No.:
    HY-13986
    Quantity:
    MCE Japan Authorized Agent: